NEW YORK, NY--(Marketwire - September 21, 2007) - Taglich Brothers, Inc. announces it initiated coverage of GammaCan International, Inc. (OTCBB: GCAN).

GammaCan Internatinal, Inc., headquartered in Kiryat Ono, Israel, has been active in the development of intravenous immunoglobulin therapy for cancer since 2004. The company's lead product, VitiGam™, is aimed at treating stage III and IV melanoma with immunotherapy. The company is also developing an anti-angiogenesis agent as a cancer treatment.

The complete 18-page report is available at

Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the Company mentioned in this report: All research issued by Taglich Brothers, Inc. is based on public information. The company paid a $5,000 (USD) engagement fee in August 2007 and will, commencing upon distribution of our initial report, pay $1,750 (USD) per month for the creation and dissemination of research reports.

For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.

Contact Information: Contact: Richard Oh Taglich Brothers, Inc. 631-757-1500